Biotech-компания ImmunityBio выросла на 22% благодаря сильным прогнозам по препарату от рака мочевого пузыря, акции Coupang поднялись после повышения рейтинга Deutsche Bank
На фондовом рынке произошло несколько значительных изменений.
ImmunityBio
Price: 1.70Company and Business Model
ImmunityBio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. Its core products include novel therapies that leverage the immune system to target tumors and viral infections. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales. ImmunityBio is currently in the clinical trial phase for several of its therapies, which are aimed at addressing unmet medical needs in oncology and infectious disease treatment.
Investment Profile
The investment profile of ImmunityBio suggests it may be more suitable for growth investors, given its focus on innovative therapies and potential future market opportunities. However, the company's significant risks and recent financial performance indicate a high level of uncertainty. Investors should consider their risk tolerance and investment strategy when evaluating this stock.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- -0.58 Risk
- Revenue QoQ — quarter-over-quarter revenue growth
- -100.0% ↓
- EPS surprise
- -16.7% worse than expected
- 20d volatility
- 5.4% normal
FMP / FinFeed data updated:
2026-06-10
Reco: Sell
Potential: 20
Risk: 80
Updated: 2026-06-11 05:21
How recommendation works
Why AI thinks so:
Weak fundamentals and negative momentum indicate high risk.
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-05-08 15:23 | — | Sell | scenario_deterioration |
| 2026-05-08 05:19 | Sell | Sell | scenario_deterioration |
| 2026-04-17 02:46 | Hold | Sell | Компания демонстрирует высокую волатильность и отрицательные финансовые показатели, что указывает на значительные риски. Однако недавний рост на 51.80% за 120 дней может свидетельствовать о потенциальных возможностях для |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-08 10:30 | Raymond James | Update | — → 5 | 1.82 |
| 2025-10-17 10:19 | Leerink Partners | Update | — → 2 | 0.8455 |